Swixx BioPharma, which also has the exclusive contract for Amryt’s Myalepta, will start deliveries later this month.
Lojuxta, also known as lomitapide, has been developed to treat adults with a rare cholesterol disorder.
“Lomitapide is an important contributor to Amryt’s commercial performance and growth and today’s announcement demonstrates the progress we are making in expanding lomitapide’s reach in existing and new territories,” said chief executive Joe Wiley in a statement
“This agreement will help bring lomitapide to even more patients in need. Also, we are excited to grow and consolidate our existing partnership with Swixx who currently distribute metreleptin exclusively across the CEE territories.”